Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

被引：0
|
作者：
MerriKay Oleen-Burkey
Anissa Cyhaniuk
Eric Swallow
机构：
[1] Outcomes Scribe,
[2] LLC,undefined
[3] Formerly,undefined
[4] Health Economics and Outcomes Research,undefined
[5] Teva Pharmaceuticals,undefined
[6] OptumInsight Life Sciences,undefined
来源：
BMC Neurology | / 14卷
关键词：
Multiple sclerosis; Disease-modifying therapy; Persistence; Treatment gaps; Therapy re-initiaton; Therapy switching; Therapy discontinuation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010
    Oleen-Burkey, MerriKay
    Cyhaniuk, Anissa
    Swallow, Eric
    BMC NEUROLOGY, 2014, 14
  • [2] Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis
    Korn, Jonathan
    Medin, Jennie
    Fang, Juanzhi
    Putzki, Norman
    NEUROLOGY, 2017, 88
  • [3] Adherence and Persistence to Disease-Modifying Therapies for Multiple Sclerosis and Their Impact on Clinical and Economic Outcomes in a US Claims Database
    Pineda, Elmor
    Ng, Carmen
    Sheinson, Daniel
    Bonine, Nicole
    Pardo, Gabriel
    NEUROLOGY, 2021, 96 (15)
  • [4] Adherence to glatiramer acetate 40mg versus oral disease-modifying therapies for multiple sclerosis
    Halpern, R.
    Wolbeck, R.
    Blauer-Peterson, C.
    Wu, Y.
    Gandhi, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 685 - 685
  • [5] PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES MARKETED IN THE US
    Bin Sawad, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    VALUE IN HEALTH, 2015, 18 (03) : A282 - A282
  • [6] A cost analysis of drug-related monitoring requirements for glatiramer acetate and other multiple sclerosis disease-modifying therapies
    Wu, Ying
    van Engen, Anke
    Tchoukouaha, Thierry
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 143 - 143
  • [7] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [8] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [9] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
  • [10] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
12345